Project Overview +

This study examines the agreement between prospective and retrospective reporting of toxicities and health care service use (e.g., unscheduled office visit, emergency department visit, hospitalization) by patients with cancer treated with systemic chemotherapy. This information will provide the Cancer Center with rich patient outcomes data to inform quality improvement efforts.

Aims +

Aim 1. Assess the agreement among prospective, retrospective, and medical record reporting of chemotherapy toxicities and health care service use.

Aim 2.
Investigate the relationship between toxicity and health care service use.

Participants +

150 patients with invasive breast, non-small cell lung, colorectal, and head and neck cancers who are scheduled to initiate a new chemotherapy regimen at the University of Michigan Comprehensive Cancer Center.

Intervention +

Enroll 150 adult patients with non-Hodgkin lymphoma, female breast, colorectal, non-small cell lung, and head and neck cancers about to receive their first cycle of chemotherapy at the University of Michigan Comprehensive Cancer Center.

We perform daily prospective assessment of toxicity and service use by IVR questionnaires Days 1-21 after chemotherapy followed by retrospective IVR and paper questionnaires on Day 30.

We use descriptive statistics to examine the frequency, timing, and severity of toxicities across the patient sample and correlate toxicities and toxicity-related health care service use. Second, we compare agreement between a) prospective and retrospective toxicity reports, and b) IVR- versus paper- completed retrospective toxicity reports.

Measuring Chemotoxicity with IVR

09/01/2011 - 08/31/2012

Sponsor(s)

National Cancer Institute

Principal Investigator:

Christopher R. Friese, PhD, RN, AOCN, FAAN

Co-Investigator(s):

Jennifer J. Griggs, MD, MPH
Yun Li, PhD